Is Centralisation of Cancer Services Associated With Under‐Treatment of Patients With High‐Risk Prostate Cancer?—A National Population‐Based Study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70403 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Lu Han und 11 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Public Health and Policy, The London School of Hygiene and Tropical Medicine, London, UK. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Health Services Accessibility. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.
Abstract (Originalsprache)
Background
Centralising prostate cancer surgical and radiotherapy services, requires some patients to travel longer to access treatment, but its impact on actual treatment utilisation and outcomes is unknown.
Methods
Using national cancer registry records linked to administrative hospital data, we identified all patients with high risk and locally advanced prostate cancer diagnosed between 1 April 2019 and 31 March 2020 in the English National Health Service ( n = 15,971). Estimated travel times from the patient residential areas to the nearest hospital providing surgery or radiotherapy were estimated for journeys by car and by public transport. Multivariable logistic regression was used to model relationships between travel time and receipt of care with adjustment for patient characteristics.
Results
10,693 (67%) men received radical surgery or radiotherapy (RT) within 12 months of diagnosis. Average travel time to the nearest hospital providing prostatectomy or RT was 23.2 min by private car and 58.2 min by public transport. We found no association between travel time, either by car or public transport and the likelihood of receiving curative treatment. Patients living in the most socially deprived areas, those aged over 70, those with two or more comorbidities, and those of black ethnic origin, were less likely to receive curative treatment ( p & =& 0.001 for all associations).
Conclusions
The current configuration of national prostate cancer services is not associated with the likelihood of receiving curative treatment. Further increases in capacity will unlikely improve utilisation rates beyond addressing sociodemographic barriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Public Health and Policy, The London School of Hygiene and Tropical Medicine, London, UK.
- Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
- Institute of Cancer Policy-King's College London, London, UK.
- Department of Urology, University College London, London, UK.
- Department of Radiotherapy, The Royal Marsden Hospital, London, UK.
- Department of Urology, The Christie NHS Trust, London, UK.
ORCID-Profile: Lu Han, Ajay Aggarwal
Förderung
- National Institute for Health and Care Research
Zitieren
APA
Han, L., Mayne, E., Dodkins, J., Sullivan, R., Cook, A., Parry, M., Nossiter, J., Cowling, T. E., Tree, A., Clarke, N., van der Meulen, J., & Aggarwal, A. (2024). Is Centralisation of Cancer Services Associated With Under‐Treatment of Patients With High‐Risk Prostate Cancer?—A National Population‐Based Study. Cancer Medicine. https://doi.org/10.1002/cam4.70403
Vancouver
Han L, Mayne E, Dodkins J, Sullivan R, Cook A, Parry M, et al. Is Centralisation of Cancer Services Associated With Under‐Treatment of Patients With High‐Risk Prostate Cancer?—A National Population‐Based Study. Cancer Medicine. 2024. doi:10.1002/cam4.70403
BibTeX
@article{Han2024,
author = {Han, Lu and Mayne, Emily and Dodkins, Joanna and Sullivan, Richard and Cook, Adrian and Parry, Matthew and Nossiter, Julie and Cowling, Thomas E and Tree, Alison and Clarke, Noel and van der Meulen, Jan and Aggarwal, Ajay},
title = {Is Centralisation of Cancer Services Associated With Under‐Treatment of Patients With High‐Risk Prostate Cancer?—A National Population‐Based Study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70403}
}
EUVIMED